m+Medelevator.RU
← Поиск публикаций
Natural product research · 2022

Comparison monoterpene and sesquiterpene, herbage yield of Satureja hortensis, Thymus vulgaris, and Salvia officinalis from the Fars province of Iran.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Mohammadian Yasuj Seyedeh Fariba, Najafian Sharareh, Hosseinifarahi Mehdi

Аннотация

Recently, numerous side effects of synthetic drugs have led to using medicinal plants as a reliable source of new therapy. Pain is a global public health problem with a high impact on life quality and a huge economic implication, becoming one of the most important enemies in modern medicine. The medicinal use of plants as analgesic or antinociceptive drugs in traditional therapy is estimated to be about 80% of the world population. The lamiaceae family, one of the most important herbal families, incorporates a wide variety of plants with biological and medical applications. In this study, the main active compounds of Thymus vulgaris (thymol (51.59%), p-cymene (15.41%), carvacrol (4.52%) and γ-terpinene (12.63%), Salvia officinalis; cis-thujone (38.05%), camphor (16.08%), 1,8-cineole (11.97%), trans-thujone (5.88%), camphene (4.79%), α -pinene (4.69%) and carvacrol (50.68%), γ-terpinene (34.44%) and α-terpinene (3.72%) in Satureja hortensis was determined. The highest EO contents (w/w %) was obtained in the plants of summer savory (2.05%), followed by the garden thyme (1.83%) and common sage (0.55%). It is necessary to identify the most effective compounds in order to extract or synthesise in pure form for future use in the pharmaceutical industry. Also, might be used for isolation of potentially active compounds from some of these medicinal plants in future and formulation of commercial therapeutic agents.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты